Background and Aims Pharmacokinetic data for proton pump inhibitors (PPIs), acid-suppression drugs commonly prescribed to children, are lacking for obese children who are at greatest risk for acid-related disease. In a recent multi-center investigation, we demonstrated decreased, total body weight adjusted, apparent clearance (CL/F) of the PPI pantoprazole for obese children compared with their non-obese peers. Subsequently, we developed a population-based pharmacokinetic (PopPK) model to characterize pantoprazole disposition and evaluated appropriate pantoprazole dosing strategies for obese pediatric patients, using simulation. Methods Pharmacokinetic data from the only prospective study of PPIs in obese children (aged 6-17 years; n = 40) included 273 pantoprazole and 256 pantoprazole-sulfone plasma concentrations, after single oral-dose administration, and were used for pantoprazole model development and covariate analysis (NONMEM ® ). Model evaluation was performed via bootstrapping and predictive checks, and the final model was applied to simulate systemic pantoprazole exposures for common dosing scenarios. Results A two-compartment PopPK model, which included CYP2C19 genotype and total body weight, provided the best fit. Resultant, typical, weight-normalized pantoprazole parameter estimates were different than previously reported for children or adults, with significantly reduced pantoprazole CL/F for obese children. Of the dosing scenarios evaluated, the weight-tiered approach, approved by the US Food and Drug Administration, achieved pantoprazole exposures [area under the curve (AUC 0-∞ )] within ranges previously reported as therapeutic, without over-or under-prediction for obese children. Conclusions Our data argue against empiric dose escalation of PPIs for obese children and support current FDA-approved pediatric weight-tiered dosing for pantoprazole; however, 3-to 5-fold inter-individual variability in pantoprazole AUC 0-∞ remained using this dosing approach.
Introduction
Proton pump inhibitors (PPIs) are potent acid-suppression drugs that are commonly prescribed to children [1] . Obese children [defined by body mass index (BMI) ≥ 95th percentile for age] [2] are six times more likely than nonobese children to have gastroesophageal reflux disease (GERD) [3] , a condition for which PPIs have become the mainstay of therapy [4] . Currently, dosing recommendations for PPIs are lacking for obese children.
Obesity-related changes in physiology-such as changes in tissue composition and proportion of lean to total body mass [5] , increased blood volume and cardiac output [6] , decreased kidney and liver function [7] , and altered regional blood flow [8] , protein binding, and drug metabolism [9] -can affect drug pharmacokinetics [5-8, 10, 11] . In a recently completed, multi-center investigation of PPI disposition in obese children, we demonstrated decreased clearance and increased systemic exposure for the PPI pantoprazole in obese children and adolescents compared with historical non-obese pediatric peers [9] , highlighting an increased risk for systemic PPI overexposure for obese pediatric patients if total body weight (TBW) dosing is employed, as is common in pediatric practice. Emerging evidence suggests that systemic overexposure to PPIs, specifically area under the concentration time curve (AUC) and peak plasma concentration (C max ), may be associated with PPI-related adverse events such as osteopenic fractures, particularly with prolonged PPI treatment [12] . To help minimize the risk of PPI overexposure for obese children, based on our pharmacokinetic data, we developed a population-based pharmacokinetics model to characterize pantoprazole disposition and evaluated appropriate pantoprazole dosing strategies for obese children.
Methods

Study Design
Pharmacokinetics data from a prospective, multi-center, open-label, single-oral-dose investigation of pantoprazole in 40 obese children (BMI ≥ 95th percentile for age, aged 6-17 years) were used for model development. This study (www.clini caltr ials.gov NCT02186652) was conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the current revision of the Declaration of Helsinki. Study participants received pantoprazole (PROTONIX ® delayed-release tablets, Wyeth Pharmaceuticals, Inc., Philadelphia, PA, USA), approximately 1.2 mg per lean body weight (LBW) kilogram calculated via a validated LBW equation [13] , rounded to the nearest whole tablet and up to a total maximum dose of 80 mg. All children were genotyped for CYP2C19, the primary drug metabolizing pathway for pantoprazole clearance.
Bioanalytical Methods
Pantoprazole and pantoprazole-sulfone concentrations in plasma were quantified by the Pediatric Trials Network's central laboratory (OpAns, LLC, Durham, NC, USA) using a validated high-performance liquid chromatography tandem mass spectrometry (HPLC/MS-MS) assay. The lower limit of quantification for both pantoprazole and pantoprazolesulfone was 10 ng/mL. During method validation, accuracy and precision of all sample runs were within the FDA bioanalytical assay validation criteria (e.g., ± 15%).
Data Analysis
Pantoprazole plasma pharmacokinetics data, following single-time oral administration, were analyzed with a nonlinear mixed effects modeling approach using the software NONMEM ® (version 7.2, Icon Solutions, Ellicott City, MD, USA). The first-order conditional estimation method with interaction was used for all model runs. Run management was performed using Pirana (version 2.8.1) [14] . Visual predictive checks and bootstrap methods were performed with Perl-speaks-NONMEM ® (version 3.6.2) [15] . Data manipulation and visualization were performed using the software Stata (version 13.1, College Station, TX, USA), R (version 3.0.2, R Foundation for Statistical Computing, Vienna, Austria), and RStudio (version 0.97.551, RStudio, Boston, MA, USA) with the packages lattice, Xpose, and ggplot2 used for the latter [16] .
Based on visual inspection of the pharmacokinetics data and a review of the primary literature, one-and two-compartment pharmacokinetics models were evaluated for both pantoprazole and pantoprazole-sulfone using the ADVAN2 TRANS2 and ADVAN4 TRANS4 subroutines, respectively, in NONMEM ® . The population pharmacokinetics analysis was performed using the total dose of pantoprazole, with concentrations of pantoprazole and pantoprazole-sulfone modeled sequentially. The pharmacokinetics parameter estimates from the final model for pantoprazole were fixed in the combined model for pantoprazole and pantoprazole-sulfone (Suppl. Fig. 1 ). As the fraction of pantoprazole converted to pantoprazole-sulfone has not been reported in the literature, it was fixed to 1 to have an identifiable pharmacokinetics model. Various absorption pharmacokinetics models-including a lag time model, transit compartment model, Erlang absorption model, Weibull absorption model, and sigmoidal Emax absorption model-were evaluated to characterize the delayed absorption of the pantoprazole delayed-release tablet formulation [17] [18] [19] [20] .
Established methods for addressing bias introduced by below quantification limit (BQL) samples in population pharmacokinetics modeling-including methods M1 (discard all BQL samples), M3 (likelihood-based), M5 (replace BQL samples with the lower limit of quantification [LLOQ]/2), M7 (replace BQL samples with 0), and an all-data approach (include all BQL samples)-were evaluated for BQL samples occurring prior to C max [21, 22] . In addition, replacing the BQL data closest and prior to the first measurable pharmacokinetics sample with the LLOQ/2 or 0 was tested. For samples occurring after C max , half the quantification limit was assigned for a single BQL sample, or 0 was assigned for all values in consecutive samples that are BQL. Inter-individual variability (IIV) was assessed for pharmacokinetics model parameters using an exponential relationship (Eq. 1). Estimation of a covariance matrix for IIV on clearance (CL) and volume (V) was attempted.
where Pij denotes the estimate of parameter j in the ith individual, θ Pop,j is the population value for parameter j, and ηij denotes the deviation from the average population value for parameter j in the ith individual. The random variable η is assumed to be normally distributed with a mean 0 and variance ω 2 . Proportional, additive, and combined (proportional plus additive) residual error models were evaluated (Eqs. 2-4).
where C obs,ij is the jth observed pantoprazole concentration in the ith individual; C pred,ij is the jth predicted concentration in the ith individual; ε prop,ij and ε add,ij are random variables with mean 0 and variance σ prop,ij 2 and σ add,ij 2 , respectively. Body size measurements [lean body mass (LBM), fat-free mass (FFM), and normal fat mass (NFM)] were calculated using TBW and body height (HT), as shown in Eqs. 9-12 [24] [25] [26] [27] . Using a newer pediatric-specific calculation for FFM by Al-Sallami et al. [28] did not improve the Δ in objective function value (OFV; data not shown).
(1) where F fat is a parameter that accounts for a different contribution of fat mass. The relationship between body size measurements (TBW, LBM, FFM, and NFM) and pharmacokinetics parameters (CL and V) was explored using a fixed exponent allometric relationship, as shown in Eq. 13 [26, 29, 30] .
where P ij is the estimate of parameter j in the ith individual, W i is a measure of body size (TBW, LBM, FFM, or NFM) in the ith individual, and P j is the parameter in an individual with a standard measure of body size (W std ). W std is 70, 70, 56, and 52 kg, for TBW, NFM, FFM, and LBM, respectively. The exponent PW is 0.75 for clearance parameters (CL, Q) and 1 for distribution volumes (V c , V p ).
Covariate Model
The potential effects of clinically significant covariates on pharmacokinetics parameters were evaluated if a relationship was suggested by visual inspection of scatter and box plots (continuous and categorical variables, respectively) of the individual deviations from the population-typical value pharmacokinetics parameters (ETAs) against covariates. The following covariates were explored: age, age group (i.e., adolescent vs child), body mass index (BMI), BMI percentile (PBMI), morbid obesity (BMI ≥ 99th percentile), race, sex, LBM, FFM, NFM, waist: hip ratio, CYP2C19 genotype (number of functional alleles), and resting energy expenditure (REE). A forward inclusion (p < 0.05 and ΔOFV > 3.8) and backward elimination (p < 0.01 and ΔOFV > 6.6) approach was used to evaluate statistical significance of relevant covariates.
With the exception of body size measurements (TBW, LBM, FFM, and NFM) and CYP2C19 genotype, continuous covariates were normalized to the population median value as described in Eq. 14, whereas for categorical covariates such as morbid obesity, a relationship as shown in Eq. 15 was used, ( 
7)
For female FFM = 37.99 * TBW * HT 2 35 .98 * HT 2 + TBW ,
where cov i denotes the individual covariate value; cov m is the population median covariate value; θ cov is a parameter that represents the covariate effect; and MORBID OBESITY is a categorical variable that takes on a value of unity when morbidly obese and 0 when non-morbidly obese.
Effect of CYP2C19 genotype (number of functional alleles) on clearance was evaluated as a continuous variable using Eqs. 16-18. In Eqs. 12-14, TBW i denotes the weight of an individual participant; θ CL0 is the population estimate for clearance in participants with homozygous loss-of-functional alleles for CYP2C19; θ 2C19 is a parameter that represents the influence of the number of functional alleles on clearance; n i is the CYP2C19 number of functional alleles; and CL i is the estimate of CL of an individual participant.
Model Evaluation
During the population pharmacokinetics model-building process, successful minimization, diagnostic plots, plausibility and precision of parameter estimates, objective function, shrinkage values, and visual predictive checks were used to assess model appropriateness.
Parameter precision for the final population pharmacokinetics model was evaluated using non-parametric bootstrapping (1000 replicates) to generate the 95% confidence intervals for parameter estimates. Standardized visual predictive checks were performed for the final models by generating 1000 Monte Carlo simulation replicates per time point of pantoprazole exposure. Simulated results were compared at the participant level with those observed in the study by calculating and plotting the percentile of each observed concentration in relation to its 1000 simulated observations derived from the final model [31] . The dosing and covariate values used to generate the simulations in the standardized visual predictive check were the same as those used in the study population. The number of observed concentrations outside the 90% prediction interval for each time point was quantified.
Simulation
The modeling results were applied to simulate systemic exposure to pantoprazole (C max and AUC 0-∞ ) after singletime oral drug administration for obese children and adolescents following three different dosing scenarios: (i) FDAapproved TBW-tiered dosing for children aged ≥ 5 years (20 mg if ≥ 15 kg to < 40 kg, and 40 mg if ≥ 40 kg); (ii) 1 mg/ kg TBW dosing with a maximum dose of 80 mg, chosen because it falls in the dosing range commonly employed in clinical practice [32] ; and (iii) 1.2 mg/kg LBW dosing with a maximum dose of 80 mg, recently suggested to be a more appropriate dosing strategy than TBW-based dosing for obese children [9] . 
Results
Analysis Population
Population Pharmacokinetics Modeling Results
A two-compartment population pharmacokinetics model for both pantoprazole and pantoprazole-sulfone provided the best fit of the data (Fig. 1) , while the transit compartment model best characterized the delayed absorption pharmacokinetics profiles of pantoprazole. One subject with an atypical absorption profile and one subject with 90% of samples BQL were excluded from the final model (n = 38). The M1 method (discard all BQL samples) was selected for addressing bias introduced by BQL samples, as it provided a reasonable fit without convergence issues. Scaling of apparent clearance (CL/F) and apparent volume of distribution (V/F) parameters by TBW using a fixed exponent allometric relationship (exponent = 0.75 for CL/F and 1 for V/F) resulted in the largest reduction in the OFV (∆OFV = − 61.72) compared with LBM (∆OFV = − 58.72), FFM (∆OFV = − 56.1), and NFM (∆OFV = − 62.36) after adjusting for the number of parameters in the model. Additionally, estimating the exponent of TBW on CL/F parameters did not result in a significant drop in OFV (∆OFV = − 0.25) compared with a fixed exponent allometric relationship. Visual inspection of covariate-parameter relationships identified a relationship between the number of CYP2C19 functional alleles and CL/F (Fig. 2) . After incorporating body size, use of a square-root function to quantify the effect of the number of CYP2C19 functional alleles on CL/F resulted in the largest drop in OFV (∆OFV = − 24.32) compared with other covariates. Incorporation of an effect of waist: hip ratio on V/F and an effect of age on CL/F using a power function also resulted in a significant drop in the OFV; however, only the effect of CYP2C19 genotype on CL/F was retained after backward elimination.
Standard goodness-of-fit and residual plots of the final model indicated some under-prediction of concentrations at earlier time points; however, considering the large proportion of BQL samples at earlier time points (32 out of 37 pantoprazole samples at 1 h and 12 out of 40 pantoprazolesulfone samples at 1.5 h), the model showed good predictability (Fig. 3) .
The estimated values for the population pharmacokinetics parameters, covariate and variability, along with the standard error of these estimates and bootstrap medians and the 95% confidence intervals for these values, are summarized in Table 2 . In the final model, ETA shrinkage for CL/F, mean transit time (MTT), apparent clearance for pantoprazole-sulfone (CLm/F), apparent volume of distribution for central compartment for pantoprazole-sulfone (Vcm/F), apparent distributional clearance for pantoprazole-sulfone (Qm/F), and apparent volume of distribution for peripheral compartment for pantoprazole-sulfone (Vpm/F) were 2, 0, 6, 6, 24, and 14%, respectively, while epsilon shrinkage values were 9 and 24% for pantoprazole and pantoprazole-sulfone, respectively.
Empirical Bayesian estimates (EBEs) obtained from the final model were stratified by age and CYP2C19 genotype (Table 3) . Excluding the only CYP2C19 PM, individual subject post hoc CL/F estimates appeared to be higher in children (n = 18; 6-11 years) compared with adolescents (n = 19; 12-17 years). Half-life was shorter in children, as would be expected with the higher clearance. CL/F in CYP2C19 EMs was consistently higher than that in CYP2C19 IMs.
Model Evaluation
The model for pantoprazole and pantoprazole-sulfone was evaluated using a 500-set bootstrap analysis; 83% of bootstrap datasets converged to > 3 significant digits. The medians of bootstrap fixed effects parameter estimates were within 6.4% of population estimates from the original dataset for all parameters. The standardized visual predictive check revealed a reasonable fit between the observed and predicted pantoprazole and pantoprazole-sulfone concentrations. A uniform distribution of calculated observation percentiles over the majority of time after dose was observed for pantoprazole and pantoprazole-sulfone (Fig. 4) . There was some bias toward under-prediction for samples collected at earlier time points. Overall, the percentage of observed concentrations outside of the 90% prediction interval for pantoprazole and its metabolite pantoprazole-sulfone were 10.5% and 4.4%, respectively. The classic visual predictive check showed that the model adequately described the data; the percentages of observed concentrations outside of the 90% prediction interval for pantoprazole and its metabolite were 10.1% and 4.8%, respectively (Fig. 5 ). Table 4 summarizes the comparison of pantoprazole pharmacokinetics exposures (C max and AUC 0-∞ ) using the population pharmacokinetics model for obese children and adolescents, following three dosing scenarios (i.e., FDAapproved weight-tiered dosing, 1.0 mg/kg TBW dosing, and 1.2 mg/kg LBW dosing), to published values for nonobese peers and adults following FDA-approved dosing regimens. Among the three evaluated dosing scenarios for pediatric obese patients, the FDA-approved weight-tiered dosing regimen provided the most comparable C max and AUC 0-∞ to non-obese peers and non-obese adults. Both TBW-based dosing and LBW-based dosing for obese patients resulted in higher C max and AUC 0-∞ values than the FDA-approved weight-tiered dosing regimen, with 1.0 mg/TBW-based dosing leading to the highest C max and AUC 0-∞ for obese pediatric patients. As expected from the 500% reduction in CL/F observed in the only CYP2C19 PM (Table 3) , C max and AUC 0-∞ were significantly higher for the PM (data not shown). For CYP2C19 non-PMs (n = 37), all dosing scenarios resulted in an approximately twofold IIV in pantoprazole C max and 3-to fivefold IIV in pantoprazole AUC 0-∞ (Table 4 ). In the absence of pediatric-specific drug exposure-response data for pantoprazole, we compared the drug exposures (AUC 0-∞ ) achieved in the dosing simulations to pantoprazole exposure-response data available for adults (Fig. 6 ). For the most part, systemic exposures achieved for obese pediatric patients fell within pantoprazole AUC 0-∞ ranges associated with therapeutic treatment response (e.g., gastric acidity reduction) in adults receiving 40 mg of oral pantoprazole [34] [35] [36] . Although all three dosing strategies successfully avoided subtherapeutic pantoprazole AUC 0-∞ ranges for obese children and adolescents, only the FDA-approved weight-tiered approach avoided systemic exposures above the therapeutic range for adults (Fig. 6 ).
Dosing Scenario Simulation Results
Discussion
Our study illustrates that the typical TBW-normalized pharmacokinetics parameter estimates for pantoprazole, previously reported in the literature for children 6-16 years of age [33, 37] , do not apply to obese children and adolescents ( Table 2 ). The typical pantoprazole CL/F for obese children (aged 6-11 years) ranged between 0.06 and 0.2 L/kg/h, and for obese adolescents (aged 12-17 years) between 0.04 and 0.15 L/kg/h (compared with 0.4 ± 0.22 and 0.18 ± 0.08 L/kg/h, respectively, previously reported [33] . The absorption rate constant (Ka) estimate in our study, median 7.5 h −1 (95% CI 2.7-12.2) ( Table 2) , was greater than the median 1.3 h −1 (95% CI 1.05-1.92) previously reported in a pediatric population analysis by Knebel et al. [38] ; however, this may be related to differences in the absorption models used and/or the fasting state of participants in our study but not in the Knebel et al. study [38] .
Previous studies in children [37, 38] and adults [39] identified CYP2C19 genotype as a significant covariate for pantoprazole pharmacokinetics. In our population analysis, the number of CYP2C19 functional alleles explained variability in pantoprazole CL/F (Fig. 2a) . Compared with CYP2C19 EMs (two functional alleles), the median pantoprazole CL/F was estimated to be reduced by 18% for IMs (one functional allele) and by > 500% for PMs (no functional alleles) ( Table 3) . Ratios of CL/F estimates from our population analysis for IM: EM (0.76) and PM: EM (0.18) were comparable to those previously reported for children [37] .
Consistent with previous observations of an age effect for CYP2C19 [33, 37, 38] , our population pharmacokineticsderived parameter estimates for CYP2C19 non-PMs (n = 37) demonstrated a shorter half-life (t ½ ) and higher CL/F for the CYP2C19 substrate pantoprazole in obese children compared with adolescents (Table 3) . However, after incorporating CYP2C19 genotype, age was not identified as a significant covariate in the final population pharmacokinetics model, likely due to the relatively small sample size (n = 18 children and n = 19 adolescents) and the substantial variability in CL/F. Sex was not identified as a significant covariate, consistent with previous studies [33, 37, 38] . Thus, the final population pharmacokinetics model included genotype and TBW as covariates.
We previously observed that LBW may be a better dosing predictor than TBW for obese pediatric patients [9] . However, in our population pharmacokinetics analysis, LBW failed to account for pantoprazole pharmacokinetics variability any better than TBW. This observation may be explained by a high correlation between LBW and TBW observed in our study population (ρ = 0.91). Other anthropometric parameters (e.g., waist: hip ratio, resting energy expenditure) were not identified as significant model covariates. To fill the gap in dosing recommendations for obese pediatric patients, individual estimates from the final model were used to assess the effect of three different dosing strategies on pantoprazole exposures for obese pediatric patients: FDA-approved weight-tiered dosing, LBW-based dosing, and TBW-based dosing. Pantoprazole exposures (C max and AUC 0-∞ ) in obese children and adolescents following the FDA-approved weight-tiered dosing were most comparable to those achieved in non-obese historical peers and nonobese adults using current FDA-approved dosing; whereas, both LBW-and TBW-based dosing resulted in exposures approximately twofold greater than reports in non-obese children and adults (Table 4) . Given growing concerns regarding the association between PPI overexposure and adverse events (e.g., osteopenia, factures) [12, 32] , our population data suggest that current FDA-approved weight-tiered dosing for pantoprazole is appropriate for obese pediatric patients.
In contrast to traditional mg-per-kg dosing practices commonly employed in pediatrics [11] , where bigger patients receive higher doses of drug, our data argue against empiric dose escalation of PPIs for obese pediatric patients. In Table 2 Parameter estimates for the final population pharmacokinetic model for pantoprazole and pantoprazole-sulfone , where CL0 = 1.45; 2C19 = 4.64; n 1 is the CYP2C19 number of functional alleles for the individual; and TBW is the weight of the individual a 1000 Bootstrap runs were performed for pantoprazole pharmacokinetic parameters (Ka, θ CL0 , θ 2C19 , Vc/F, Q/F, Vp/F, N, MTT); 500 bootstrap runs were performed for pantoprazole-sulfone pharmacokinetic parameters (CLm/F, Vcm/F, Qm/F, Vpm/F), inter-individual variability, and residual error parameters b Pharmacokinetics parameters, RSE and bootstrap results of pantoprazole were fixed to values of the final pharmacokinetics model for pantoprazole CL/F apparent clearance for pantoprazole, CLm/F apparent clearance for pantoprazole-sulfone, CV coefficient of variation, Fm bioavailability for pantoprazole-sulfone, Ka absorption rate constant, MTT mean transit time, N number of transit compartments, NA not available, Q/F apparent distributional clearance for pantoprazole, Qm/F apparent distribution clearance for pantoprazole-sulfone, RSE relative standard error, Vc/F apparent volume for central compartment for pantoprazole, Vcm/F apparent volume for central compartment for pantoprazole-sulfone, Vp/F apparent volume for peripheral compartment for pantoprazole, Vpm/F apparent volume for peripheral compartment for pantoprazole-sulfone Open circles contain the observed data collected across all subjects addition, these data contradict findings reported in a study of obese adults by Chen et al., which suggested that obese patients need double the pantoprazole dose of non-obese patients to achieve mucosal healing from acid damage [40] ; however, pharmacokinetics data were not provided in the adult study. To our knowledge, pantoprazole pharmacokinetics data are lacking in obese adult individuals, as traditionally, these individuals are excluded from clinical trials. Although it is unknown why obesity-related alterations in pharmacokinetics/pharmacodynamics may differ between children and adults, such differences have been described for some antimicrobials (e.g., cefazolin) but not others (e.g., tobramycin, gentamycin) [35] . It remains to be seen whether the obesity-related changes in pantoprazole pharmacokinetics observed in our pediatric study are true for other PPIs, or other CYP2C19 substrates prescribed to children, and how these differences may impact pharmacodynamics in obese children.
In the absence of pediatric pharmacodynamic exposure-response data for pantoprazole, we compared the average exposures achieved using the FDA-approved weighttiered dosing for obese children (C max 3.69 ± 1.08 μg/ mL, AUC 0-∞ 5.9 ± 2.0 μg*h/mL) and adolescents (C max 2.58 ± 0.61 μg/mL, AUC 0-∞ 4.7 ± 1.9 μg*h/mL) with data available in adults (C max 2.51 ± 0.67 μg/mL, AUC 0-∞ Table 4 C max and AUC 0-∞ predicted using a population pharmacokinetic model in CYP2C19 non-PM obese children and adolescents, following the FDA-approved weight-tiered dosing, total body weight-based dosing, and lean body weight-based dosing, and published reported values in non-obese peers and adults A maximum dose of 80 mg was used in simulation; pharmacokinetic parameters are given as geometric mean or mean ± standard deviation (range) 4.6 ± 2.0 μg*h/mL). Exposures achieved in obese pediatric patients fell within ranges previously associated with therapeutic treatment response (e.g., gastric acidity reduction) for adults receiving 40 mg of oral pantoprazole [34, 36, 41] (Fig. 6 ). However, using this dosing approach still resulted in 3-to fivefold IIV in AUC 0-∞ . Thus, even outside of CYP2C19 phenotype extremes (e.g., PMs), which are rare, commonly encountered genetic variants in CYP2C19 may be important determinants of PPI pharmacodynamics, both in terms of PPI efficacy and potential adverse events associated with higher systemic exposures to PPIs over time (e.g., osteopenia) [12] . Although our population model is based on a relatively small sample size (n = 40), it is the only published model of PPI pharmacokinetics for obese children. Model-derived pharmacokinetics parameters were substantially different from those previously reported for non-obese children [38] , who were not included in this study, as the study objective was to describe pantoprazole pharmacokinetics specifically for obese children.
Conclusion
Our findings regarding pantoprazole pharmacokinetics in obese children and adolescents are novel, highly relevant, and clinically important in light of the pediatric obesity epidemic [42] . Clinicians currently prescribe therapies for obese children and adolescents without clear dosing recommendations for up to one in six patients [2] . In contrast to traditional mg-per-kg dosing practices commonly employed in pediatrics [11] , our simulation data argue against empiric dose escalation of PPIs for obese pediatric patients and support the current FDA-approved pantoprazole weight-tiered dosing strategy for obese children and adolescents, without dose escalation.
